Glycoengineered Outer Membrane Vesicles: A Novel Platform for Bacterial Vaccines

Nancy L. Price¹, Guillaume Goyette-Desjardins², Harald Nothaft¹, Ezequiel Valguarnera³, Christine M. Szymanski¹, Mariela Segura², and Mario F. Feldman^{1,3}

¹Department of Biological Sciences, University of Alberta Edmonton, Alberta T6G 2E9 CANADA

²Laboratory of Immunology, Faculty of Veterinary Medicine, University of Montreal Saint-Hyacinthe, Quebec, J2S 2M2 CANADA

³Department of Molecular Microbiology, Washington University School of Medicine. St Louis, MO. 63110, USA.

Suplementary Information

Figure S1. Supplementary Data. (a) The comparison of pneumococcal capsule synthesis and *E. coli* LPS/glycoprotein synthesis. (b) & (c) Sera from mice injected with geOMVs displaying pneumococcal serotype 14 capsule antigens is specific for *S. pneumoniae* serotype 14. Mouse sera from 10 animals (Day 21) were incubated in wells of ELISAs plates seeded with whole cell *S. pneumoniae* serotype 9V (b) or 14 (c). As a negative control, sera from 4 mice injected with empty control OMVs was tested on the same plate layout. Means from each group were compared and significant differences were found between control OMVs sera and CPS14 geOMVs sera in (c) (* p-value < 0.0001). No significant differences were found between groups in (b) (NS p-value = 0.45). Error bars are SD and p-values were calculated by the unpaired t-test. (d) ELISA data of the IgY response of chicken vaccinated with *Campylobacter* geOMVs. Each symbol represents data of one chicken and the median is indicated with a line. Animal sera (Day 28) was used at a dilution of 1:10.

